Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.]
| Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.] |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 |
| Descrizione fisica | 1 online resource (384 p.) |
| Disciplina | 174/.96606 |
| Altri autori (Persone) | FinegoldDavid |
| Soggetto topico |
Biotechnology industries - Moral and ethical aspects
Pharmaceutical industry - Moral and ethical aspects Business ethics - Moral and ethical aspects |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-00533-9
9786611005337 0-08-049251-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BIOINDUSTRY ETHICS; BIOINDUSTRY ETHICS; Contents; Research Team; Preface; Acknowledgments; Introduction; ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES; WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?; ETHICISTS AND THE BIOSCIENCE INDUSTRY; A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS; STRUCTURE OF THE BOOK; Merck: Staying the Course; INTRODUCTION; FOCUSING ON PATIENTS AND THE LONG TERM; ETHICS RESOURCE CENTERS; INTERNAL ETHICAL PRACTICES; ASSESSING THE IMPACT; BENEFITS OF AN ETHICAL APPROACH; ETHICAL ISSUES; DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY
CLINICAL TRIALS AND PUBLICATION OF RESULTSWHAT DRUGS TO DEVELOP; CHALLENGES FOR THE FUTURE; Genzyme: Putting Patients First; INTRODUCTION; PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES; ETHICAL ISSUES; ETHICAL MECHANISMS; SUSTAINING THE GENZYME CULTURE; CONCLUSION; Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values; INTRODUCTION; MILLENNIUM PHARMACEUTICALS INC.; INSTITUTIONALIZING CORE VALUES AND ETHICS; ETHICS EDUCATION PROGRAMS; IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS; PRESERVING A FOCUS ON CORE VALUES; THE FUTURE Maxim Pharmaceuticals (A): Internal and External DialoguesAN UNUSUAL BIOTECH LEADER; THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY; COMPANY HISTORY; EMBEDDING CORE VALUES; MECHANISMS FOR EMBEDDING CORE VALUES; BUILDING A SUCCESSFUL GLOBAL BOARD; ANNUAL STRATEGIC RETREAT; DEALING WITH ETHICAL ISSUES; MAXIM PHARMACEUTICALS (B); Diversa Inc.: Ethical Issues in Bioprospecting Partnerships; FROM BIOPIRACY TO BIOPROSPECTING; THE COMPANY; THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS; DIVERSAÌS BIODIVERSITY COLLABORATIONS; PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS ETHICAL DECISION MAKINGTOWARD THE FUTURE; DIVERSA INC. (B); DIVERSA INC. (C); DIVERSA INC. (D); Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments; INTRODUCTION; COMPANY HISTORY; BUSINESS MODEL AND ETHICAL APPROACH; EMPOWERING THE WORKFORCE; ETHICAL ISSUES AT PIPELINE; CONCLUSION; TGN Biotech: A Start-Up with Ethical Roots; WHAT NOW?; TGN BIOTECH; TGNÌS MARKET; SEMENESISTM; WHY PIGS AND WHY SEMEN?; THE ETHICAL ISSUES; MECHANISMS FOR A TRANSPARENT PROCESS; FUTURE POSSIBILITIES; WHAT NEXT?; Interleukin Genetics and Alticor: An Unlikely Partnership; INTRODUCTION COMPANY ORIGINSEXPLORING THE ETHICS OF GENETIC TESTING; FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS; PUTTING ETHICS EXPERTS IN CHARGE; APPROACH TO ETHICAL ISSUES; PROPOSED ALTICOR DEAL; INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP; CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS; Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance; INTRODUCTION; BACKGROUND; PRODUCT LAUNCH; ETHICAL CONSIDERATIONS; THE CASE FOR ETHICS; APPLICATION TO THE HUMAN GENETICS COMMISSION; PUBLIC OPPOSITION; RESULTS; THE HGC RECOMMENDATIONS; TOWARD THE FUTURE Affymetrix, Inc.: Using Corporate Ethics Advice |
| Record Nr. | UNINA-9910458955503321 |
| Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.]
| Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.] |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 |
| Descrizione fisica | 1 online resource (384 p.) |
| Disciplina | 174/.96606 |
| Altri autori (Persone) | FinegoldDavid |
| Soggetto topico |
Biotechnology industries - Moral and ethical aspects
Pharmaceutical industry - Moral and ethical aspects Business ethics - Moral and ethical aspects |
| ISBN |
1-281-00533-9
9786611005337 0-08-049251-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BIOINDUSTRY ETHICS; BIOINDUSTRY ETHICS; Contents; Research Team; Preface; Acknowledgments; Introduction; ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES; WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?; ETHICISTS AND THE BIOSCIENCE INDUSTRY; A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS; STRUCTURE OF THE BOOK; Merck: Staying the Course; INTRODUCTION; FOCUSING ON PATIENTS AND THE LONG TERM; ETHICS RESOURCE CENTERS; INTERNAL ETHICAL PRACTICES; ASSESSING THE IMPACT; BENEFITS OF AN ETHICAL APPROACH; ETHICAL ISSUES; DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY
CLINICAL TRIALS AND PUBLICATION OF RESULTSWHAT DRUGS TO DEVELOP; CHALLENGES FOR THE FUTURE; Genzyme: Putting Patients First; INTRODUCTION; PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES; ETHICAL ISSUES; ETHICAL MECHANISMS; SUSTAINING THE GENZYME CULTURE; CONCLUSION; Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values; INTRODUCTION; MILLENNIUM PHARMACEUTICALS INC.; INSTITUTIONALIZING CORE VALUES AND ETHICS; ETHICS EDUCATION PROGRAMS; IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS; PRESERVING A FOCUS ON CORE VALUES; THE FUTURE Maxim Pharmaceuticals (A): Internal and External DialoguesAN UNUSUAL BIOTECH LEADER; THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY; COMPANY HISTORY; EMBEDDING CORE VALUES; MECHANISMS FOR EMBEDDING CORE VALUES; BUILDING A SUCCESSFUL GLOBAL BOARD; ANNUAL STRATEGIC RETREAT; DEALING WITH ETHICAL ISSUES; MAXIM PHARMACEUTICALS (B); Diversa Inc.: Ethical Issues in Bioprospecting Partnerships; FROM BIOPIRACY TO BIOPROSPECTING; THE COMPANY; THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS; DIVERSAÌS BIODIVERSITY COLLABORATIONS; PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS ETHICAL DECISION MAKINGTOWARD THE FUTURE; DIVERSA INC. (B); DIVERSA INC. (C); DIVERSA INC. (D); Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments; INTRODUCTION; COMPANY HISTORY; BUSINESS MODEL AND ETHICAL APPROACH; EMPOWERING THE WORKFORCE; ETHICAL ISSUES AT PIPELINE; CONCLUSION; TGN Biotech: A Start-Up with Ethical Roots; WHAT NOW?; TGN BIOTECH; TGNÌS MARKET; SEMENESISTM; WHY PIGS AND WHY SEMEN?; THE ETHICAL ISSUES; MECHANISMS FOR A TRANSPARENT PROCESS; FUTURE POSSIBILITIES; WHAT NEXT?; Interleukin Genetics and Alticor: An Unlikely Partnership; INTRODUCTION COMPANY ORIGINSEXPLORING THE ETHICS OF GENETIC TESTING; FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS; PUTTING ETHICS EXPERTS IN CHARGE; APPROACH TO ETHICAL ISSUES; PROPOSED ALTICOR DEAL; INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP; CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS; Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance; INTRODUCTION; BACKGROUND; PRODUCT LAUNCH; ETHICAL CONSIDERATIONS; THE CASE FOR ETHICS; APPLICATION TO THE HUMAN GENETICS COMMISSION; PUBLIC OPPOSITION; RESULTS; THE HGC RECOMMENDATIONS; TOWARD THE FUTURE Affymetrix, Inc.: Using Corporate Ethics Advice |
| Record Nr. | UNINA-9910784648603321 |
| Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioindustry ethics / / David L. Finegold ... [et al.]
| Bioindustry ethics / / David L. Finegold ... [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 |
| Descrizione fisica | 1 online resource (384 p.) |
| Disciplina | 174/.96606 |
| Altri autori (Persone) | FinegoldDavid |
| Soggetto topico |
Biotechnology industries - Moral and ethical aspects
Pharmaceutical industry - Moral and ethical aspects Business ethics - Moral and ethical aspects |
| ISBN |
1-281-00533-9
9786611005337 0-08-049251-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BIOINDUSTRY ETHICS; BIOINDUSTRY ETHICS; Contents; Research Team; Preface; Acknowledgments; Introduction; ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES; WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?; ETHICISTS AND THE BIOSCIENCE INDUSTRY; A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS; STRUCTURE OF THE BOOK; Merck: Staying the Course; INTRODUCTION; FOCUSING ON PATIENTS AND THE LONG TERM; ETHICS RESOURCE CENTERS; INTERNAL ETHICAL PRACTICES; ASSESSING THE IMPACT; BENEFITS OF AN ETHICAL APPROACH; ETHICAL ISSUES; DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY
CLINICAL TRIALS AND PUBLICATION OF RESULTSWHAT DRUGS TO DEVELOP; CHALLENGES FOR THE FUTURE; Genzyme: Putting Patients First; INTRODUCTION; PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES; ETHICAL ISSUES; ETHICAL MECHANISMS; SUSTAINING THE GENZYME CULTURE; CONCLUSION; Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values; INTRODUCTION; MILLENNIUM PHARMACEUTICALS INC.; INSTITUTIONALIZING CORE VALUES AND ETHICS; ETHICS EDUCATION PROGRAMS; IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS; PRESERVING A FOCUS ON CORE VALUES; THE FUTURE Maxim Pharmaceuticals (A): Internal and External DialoguesAN UNUSUAL BIOTECH LEADER; THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY; COMPANY HISTORY; EMBEDDING CORE VALUES; MECHANISMS FOR EMBEDDING CORE VALUES; BUILDING A SUCCESSFUL GLOBAL BOARD; ANNUAL STRATEGIC RETREAT; DEALING WITH ETHICAL ISSUES; MAXIM PHARMACEUTICALS (B); Diversa Inc.: Ethical Issues in Bioprospecting Partnerships; FROM BIOPIRACY TO BIOPROSPECTING; THE COMPANY; THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS; DIVERSAÌS BIODIVERSITY COLLABORATIONS; PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS ETHICAL DECISION MAKINGTOWARD THE FUTURE; DIVERSA INC. (B); DIVERSA INC. (C); DIVERSA INC. (D); Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments; INTRODUCTION; COMPANY HISTORY; BUSINESS MODEL AND ETHICAL APPROACH; EMPOWERING THE WORKFORCE; ETHICAL ISSUES AT PIPELINE; CONCLUSION; TGN Biotech: A Start-Up with Ethical Roots; WHAT NOW?; TGN BIOTECH; TGNÌS MARKET; SEMENESISTM; WHY PIGS AND WHY SEMEN?; THE ETHICAL ISSUES; MECHANISMS FOR A TRANSPARENT PROCESS; FUTURE POSSIBILITIES; WHAT NEXT?; Interleukin Genetics and Alticor: An Unlikely Partnership; INTRODUCTION COMPANY ORIGINSEXPLORING THE ETHICS OF GENETIC TESTING; FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS; PUTTING ETHICS EXPERTS IN CHARGE; APPROACH TO ETHICAL ISSUES; PROPOSED ALTICOR DEAL; INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP; CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS; Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance; INTRODUCTION; BACKGROUND; PRODUCT LAUNCH; ETHICAL CONSIDERATIONS; THE CASE FOR ETHICS; APPLICATION TO THE HUMAN GENETICS COMMISSION; PUBLIC OPPOSITION; RESULTS; THE HGC RECOMMENDATIONS; TOWARD THE FUTURE Affymetrix, Inc.: Using Corporate Ethics Advice |
| Record Nr. | UNINA-9910809111003321 |
| Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Ghost-Managed Medicine : Big Pharma’s Invisible Hands / / Sergio Sismondo
| Ghost-Managed Medicine : Big Pharma’s Invisible Hands / / Sergio Sismondo |
| Autore | Sismondo Sergio |
| Pubbl/distr/stampa | Manchester : , : Mattering Press, , [2018] |
| Descrizione fisica | 1 online resource (231 pages) : : illustrations ; |
| Soggetto topico |
Pharmaceutical industry - Moral and ethical aspects
Drugs - Research - Moral and ethical aspects Drugs - Marketing - Moral and ethical aspects Pharmaceutical industry - Influence |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-9955277-7-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910437641703321 |
Sismondo Sergio
|
||
| Manchester : , : Mattering Press, , [2018] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The power of pills [[electronic resource] ] : social, ethical and legal issues in drug development, marketing, and pricing / / edited by Jillian Clare Cohen, Patricia Illingworth, and Udo Schüklenk
| The power of pills [[electronic resource] ] : social, ethical and legal issues in drug development, marketing, and pricing / / edited by Jillian Clare Cohen, Patricia Illingworth, and Udo Schüklenk |
| Pubbl/distr/stampa | London ; ; Ann Arbor, Mich., : Pluto, 2006 |
| Descrizione fisica | xiv, 297 p. : ill |
| Disciplina | 615/.1 |
| Altri autori (Persone) |
CohenJillian Clare
IllingworthPatricia M. L. <1954-> SchüklenkUdo |
| Soggetto topico |
Pharmaceutical policy
Pharmaceutical industry - Moral and ethical aspects Drug development |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-84964-271-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. Pharmaceutical industry, profits and obligations -- pt. 2. Justice : medicines as global public goods -- pt. 3. The social, ethical, and political challenge : neglected diseases -- pt. 4. Patents and access to medicines -- pt. 5. Research ethics -- pt. 6. Political activism and treatment access -- pt . 7. National responsibilities. |
| Record Nr. | UNINA-9910454958803321 |
| London ; ; Ann Arbor, Mich., : Pluto, 2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The power of pills [[electronic resource] ] : social, ethical and legal issues in drug development, marketing, and pricing / / edited by Jillian Clare Cohen, Patricia Illingworth, and Udo Schüklenk
| The power of pills [[electronic resource] ] : social, ethical and legal issues in drug development, marketing, and pricing / / edited by Jillian Clare Cohen, Patricia Illingworth, and Udo Schüklenk |
| Pubbl/distr/stampa | London ; ; Ann Arbor, Mich., : Pluto, 2006 |
| Descrizione fisica | xiv, 297 p. : ill |
| Disciplina | 615/.1 |
| Altri autori (Persone) |
CohenJillian Clare
IllingworthPatricia M. L. <1954-> SchüklenkUdo |
| Soggetto topico |
Pharmaceutical policy
Pharmaceutical industry - Moral and ethical aspects Drug development |
| ISBN | 1-84964-271-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. Pharmaceutical industry, profits and obligations -- pt. 2. Justice : medicines as global public goods -- pt. 3. The social, ethical, and political challenge : neglected diseases -- pt. 4. Patents and access to medicines -- pt. 5. Research ethics -- pt. 6. Political activism and treatment access -- pt . 7. National responsibilities. |
| Record Nr. | UNINA-9910778458503321 |
| London ; ; Ann Arbor, Mich., : Pluto, 2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The power of pills : social, ethical and legal issues in drug development, marketing, and pricing / / edited by Jillian Clare Cohen, Patricia Illingworth, and Udo Schüklenk
| The power of pills : social, ethical and legal issues in drug development, marketing, and pricing / / edited by Jillian Clare Cohen, Patricia Illingworth, and Udo Schüklenk |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | London ; ; Ann Arbor, Mich., : Pluto, 2006 |
| Descrizione fisica | xiv, 297 p. : ill |
| Disciplina | 615/.1 |
| Altri autori (Persone) |
CohenJillian Clare
IllingworthPatricia M. L. <1954-> SchüklenkUdo |
| Soggetto topico |
Pharmaceutical policy
Pharmaceutical industry - Moral and ethical aspects Drug development |
| ISBN | 1-84964-271-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. Pharmaceutical industry, profits and obligations -- pt. 2. Justice : medicines as global public goods -- pt. 3. The social, ethical, and political challenge : neglected diseases -- pt. 4. Patents and access to medicines -- pt. 5. Research ethics -- pt. 6. Political activism and treatment access -- pt . 7. National responsibilities. |
| Record Nr. | UNINA-9910823603503321 |
| London ; ; Ann Arbor, Mich., : Pluto, 2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
